Patient Square Capital LP — 13F Holdings & Portfolio

CIK 1819257 · latest 13F-HR filed 2026-05-15

Patient Square Capital LP manages $563.6M in 13F-reported U.S. long-equity assets across 29 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ROIV (40.13%), ARGX (4.76%), INSM (4.57%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 7 new positions, exited 6, added to 12, and trimmed 9.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$563.6M

Long-equity book

Holdings

29

Distinct positions

Period

2026-03-31

Filed 2026-05-15

Q/Q Activity

+7 / −6 / ↑12 / ↓9

vs 2025-12-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • ROIVANT SCIENCES LTD$49.0M +27.6%
  • COGENT BIOSCIENCES INC$11.7M +103.5%
  • DBV TECHNOLOGIES S A$7.6M +110.5%
  • XENON PHARMACEUTICALS INC$7.1M +115.8%
  • HARROW INC$5.5M +1590.8%
Show all 12

Top Trims

  • INSMED INC-$20.7M -44.6%
  • SPYRE THERAPEUTICS INC-$4.9M -99.0%
  • ABIVAX SA-$4.0M -23.0%
  • EYEPOINT INC-$4.0M -28.1%
  • KYMERA THERAPEUTICS INC-$2.5M -23.0%
Show all 9

New Positions

  • BELITE BIO INC$18.6M
  • LEGEND BIOTECH CORP$17.9M
  • NEKTAR THERAPEUTICS$15.1M
  • MERCK & CO INC$9.6M
  • DEFINIUM THERAPEUTICS INC$6.3M
Show all 7

Exited Positions

  • TERNS PHARMACEUTICALS INC$12.9M
  • LIQUIDIA CORPORATION$7.8M
  • OCULAR THERAPEUTIX INC$5.9M
  • DISC MEDICINE INC$5.9M
  • AVALO THERAPEUTICS INC$5.7M
Show all 6
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 ROIVANT SCIENCES LTD ROIV G76279101 $226.2M 40.13% 8,166,047 SH
2 ARGENX SE ARGX 04016X101 $26.8M 4.76% 36,718 SH
3 INSMED INC INSM 457669307 $25.8M 4.57% 157,500 SH
4 BEONE MEDICINES LTD ONC 07725L102 $23.9M 4.24% 80,542 SH
5 COGENT BIOSCIENCES INC COGT 19240Q201 $22.9M 4.07% 596,000 SH
6 MIRUM PHARMACEUTICALS INC MIRM 604749101 $21.2M 3.77% 230,000 SH
7 BELITE BIO INC BLTE 07782B104 $18.6M 3.30% 116,684 SH
8 LEGEND BIOTECH CORP LEGN 52490G102 $17.9M 3.18% 990,000 SH
9 NEKTAR THERAPEUTICS NKTR 640268306 $15.1M 2.68% 210,000 SH
10 DBV TECHNOLOGIES S A DBVT 23306J309 $14.5M 2.57% 693,534 SH
11 PHARVARIS N V PHVS N69605108 $13.9M 2.47% 493,000 SH
12 ABIVAX SA ABVX 00370M103 $13.5M 2.40% 121,245 SH
13 XENON PHARMACEUTICALS INC XENE 98420N105 $13.2M 2.34% 227,000 SH
14 CELCUITY INC CELC 15102K100 $10.8M 1.92% 95,000 SH
15 EYEPOINT INC EYPT 30233G209 $10.2M 1.82% 795,000 SH
16 MERCK & CO INC MRK 58933Y105 $9.6M 1.71% 80,000 SH
17 ARCUTIS BIOTHERAPEUTICS INC ARQT 03969K108 $9.4M 1.67% 400,645 SH
18 ALLOGENE THERAPEUTICS INC ALLO 019770106 $8.4M 1.49% 3,450,000 SH
19 KYMERA THERAPEUTICS INC KYMR 501575104 $8.3M 1.48% 100,000 SH
20 DIANTHUS THERAPEUTICS INC DNTH 252828108 $7.9M 1.40% 93,882 SH
21 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $7.8M 1.39% 200,000 SH
22 PERSPECTIVE THERAPEUTICS INC CATX 46489V302 $6.8M 1.20% 1,625,000 SH
23 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $6.3M 1.11% 331,000 SH
24 HARROW INC HROW 415858109 $5.8M 1.03% 165,209 SH
25 PROTARA THERAPEUTICS INC TARA 74365U107 $5.4M 0.95% 1,030,846 SH
26 CYTOMX THERAPEUTICS INC. CTMX 23284F105 $5.1M 0.91% 1,085,790 SH
27 ARCUS BIOSCIENCES INC RCUS 03969F109 $4.2M 0.75% 195,000 SH
28 ASSEMBLY BIOSCIENCES INC ASMB 045396207 $3.8M 0.67% 136,315 SH
29 SPYRE THERAPEUTICS INC SYRE 00773J202 $50.4K 0.01% 1,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-15 $563.6M 29 0001819257-26-000003
2025-12-31 2026-02-12 $467.1M 28 0001819257-26-000002
2025-09-30 2025-11-10 $373.9M 24 0001819257-25-000002